Favorable outcomes for both mother and baby are possible in pregnant women with Crimean-Congo hemorrhagic fever disease: a case series and literature review

Gynecol Obstet Invest. 2014;77(4):266-71. doi: 10.1159/000360699. Epub 2014 Apr 12.

Abstract

To assess the impact of Crimean-Congo hemorrhagic fever (CCHF) infection during pregnancy on maternal and fetal outcomes, we present the clinical and laboratory findings and outcomes of 5 pregnant women with CCHF infection as well as fetal outcomes. We also reviewed previously reported cases with CCHF infection in pregnant women. All pregnant women with CCHF infection who had been hospitalized between August 2007 and September 2011 were included. The gestational ages at the time of CCHF infection were 8, 18, 20, 21 and 32 weeks. CCHF infection was acquired during the 1st trimester in only 1 case and resulted in spontaneous abortion. The other 4 pregnant women completely recovered, all reached a healthy full-term gestation and 4 term babies were born. All infants had normal birth weight and were found to be healthy on their first examination and follow-up. In the literature concerning CCHF infection in pregnancy, 8 published articles including case reports or case series and 1 poster presentation including 1 case could be accessed. In conclusion, there is a risk of vertical transmission of CCHF infection, and infections acquired early in gestation had a poor prognosis for the fetus.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Combined Modality Therapy
  • Female
  • Fluid Therapy
  • Follow-Up Studies
  • Hemorrhagic Fever, Crimean / diagnosis
  • Hemorrhagic Fever, Crimean / therapy*
  • Hemorrhagic Fever, Crimean / transmission
  • Hospitalization
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical*
  • Pregnancy
  • Pregnancy Complications, Infectious / diagnosis
  • Pregnancy Complications, Infectious / therapy*
  • Ribavirin / therapeutic use
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Ribavirin